S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Canaan Inc. Secures Nasdaq Extension to Resolve Bid Price Deficiency

Canaan Inc. has been granted an additional 180-day window by Nasdaq to bring its share price back into compliance with exchange listing standards. The crypto-infrastructure firm, which recently moved its listing to the Nasdaq Capital Market, now has until January 11, 2027, to lift its bid price above the one-dollar threshold.

Canaan Inc. Secures Nasdaq Extension to Resolve Bid Price Deficiency
Photo: Bio & News

The extension follows an initial compliance period that expired on July 13, 2026. Under Nasdaq Listing Rule 5550(a)(2), companies are required to maintain a minimum closing bid price of US$1.00. While Canaan remains non-compliant with this specific pricing mandate, the company currently satisfies all other requirements for continued listing on the Nasdaq Capital Market, including those regarding the market value of publicly held shares.

Trading of Canaan’s American Depositary Shares, which trade under the symbol CAN, will remain uninterrupted throughout this second compliance period. To regain full standing, the company must ensure its closing bid price stays at or above the US$1.00 mark for at least ten consecutive business days before the January deadline. Following the company’s voluntary transfer from the Nasdaq Global Market to the Capital Market on July 1, 2026, management has stated it will continue to monitor share performance and evaluate options to address the current valuation gap.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!